Derivation for Logarithmic Trapezoidal AUC Calculation
Calculating area under the curve requires the use of two separate equations: one is follows…
Certara2015 年 8 月 5 日
Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients
Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…
Certara2015 年 7 月 23 日
Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment
Thrombomodulin alfa is a soluble recombinant human thrombomodulin that was reported to enhance the reversal…
Certara2015 年 5 月 1 日
Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis
Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…
Certara2015 年 5 月 1 日
Pediatric Drug Dosing: Tackling Big Problems for Little Patients
儿科药物开发的挑战与复杂性已广为人知。Pharmacometric modeling and simulation (M&S)…
Certara2015 年 4 月 23 日
Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers
Avibactam is a novel non-β-lactam β-lactamase inhibitor currently being assessed in combination with ceftazidime, ceftaroline…
Certara2015 年 4 月 1 日
Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9
RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low…
Certara2015 年 3 月 31 日
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-controlled Studies
Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some…
Certara2015 年 3 月 27 日
